SCHEMBL30759017

SCHEMBL30759017

Fc1ccc(I)c(Br)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345566 1.00
SCHEMBL1493833 0.85 MAOB (0.40)
SCHEMBL184417 0.79
SCHEMBL31120258 0.79
SCHEMBL4136962 0.77
SCHEMBL5194162 0.75 NTRK1 (0.41)
SCHEMBL30411804 0.75
SCHEMBL2840953 0.75
SCHEMBL79432 0.72
SCHEMBL15213955 0.72 PKM (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688776-A1 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN Acerta Pharma B.V. (NL) 2026-02-11 EP disclosed
EP-4680612-A1 CHEMICAL COMPOUNDS AN2 Therapeutics, Inc. (US) 2026-01-21 EP disclosed
EP-4573095-A1 PYRIDOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2025-06-25 EP disclosed
WO-2024201240-A1 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN ACERTA PHARMA B.V. (NL) 2024-10-03 WO disclosed
WO-2024192309-A1 CHEMICAL COMPOUNDS REACTIVE BIOSCIENCES, INC. (US) 2024-09-19 WO disclosed
WO-2024091983-A1 THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION ARTUS THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
WO-2024058815-A1 CONTINUOUS CHARACTERIZATION AND COMMUNICATION OF CHEMICAL TRACER Patina IP LLC (US) 2024-03-21 WO disclosed
WO-2024040131-A1 PYRIDOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2024-02-22 WO disclosed